A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-Overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone.

Trial Profile

A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Phase II Study to Determine the Efficacy, Tolerability and Safety of Low and High Non-Overlapping Dose Ranges of BL-1020 Compared to Placebo and Risperidone.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2012

At a glance

  • Drugs BL 1020 (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms EAGLE
  • Most Recent Events

    • 09 Oct 2012 Results from a reanalysis of the data assessing the effects of circadian rhythm on cognitive function were reported in a BioLineRx media release.
    • 27 Sep 2011 Results will be presented at the 3rd European Conference on Schizophrenia Research (ECSR).
    • 23 Sep 2009 Status changed from active, no longer recruiting to completed, based on BioLineRx media release report of final results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top